Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) Research Letter


Authors: Badar, T.; Nanaa, A.; Atallah, E.; Shallis, R. M.; Guilherme, S. D. C. C.; Goldberg, A. D.; Saliba, A. N.; Patel, A.; Bewersdorf, J. P.; DuVall, A. S.; Bradshaw, D.; Abaza, Y.; Murthy, G. S. G.; Palmisiano, N.; Zeidan, A. M.; Kota, V.; Litzow, M. R.
Title: Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Keywords: adult; cancer survival; controlled study; event free survival; aged; unclassified drug; gene mutation; major clinical study; methylation; overall survival; leukemia, myeloid, acute; allogeneic stem cell transplantation; cancer combination chemotherapy; monotherapy; antineoplastic agent; letter; antineoplastic combined chemotherapy protocols; cohort analysis; cytogenetics; data base; protein p53; tumor suppressor gene; drug combination; sulfonamides; tumor suppressor protein p53; leukemia remission; comparative effectiveness; clinical outcome; acute myeloid leukemia; hypomethylating agent; humans; human; male; female; median survival time; venetoclax; malignant neoplasm; bridged bicyclo compounds, heterocyclic
Journal Title: Blood Cancer Journal
Volume: 14
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2024-02-20
Start Page: 32
Language: English
DOI: 10.1038/s41408-024-01000-2
PUBMED: 38378617
PROVIDER: scopus
PMCID: PMC10879201
DOI/URL:
Notes: Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Aaron David Goldberg
    106 Goldberg